Clinical Trial - Trial HKUCTR-2864
Access comprehensive clinical trial information for HKUCTR-2864 through Pure Global AI's free database. This Phase 1 trial is sponsored by CStone Pharmaceuticals Aus Pty Ltd and is currently Not yet recruiting. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
HKUCTR-2864
Phase 1
Not yet recruiting
drug
Trial Details
HKU CLINICAL TRIALS REGISTRY • HKUCTR-2864
Untitled Trial
A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
Study Focus
Sponsor & Location
CStone Pharmaceuticals Aus Pty Ltd
China
Timeline & Enrollment
Phase 1
N/A
Jan 23, 2022
ICD-10 Classifications
Neoplasms
Benign neoplasms
In situ neoplasms
Personal history of other neoplasms
Benign neoplasm: Other specified sites
Data Source
HKU CLINICAL TRIALS REGISTRY
HKUCTR-2864
Non-Device Trial